Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Scand J Gastroenterol ; 53(5): 541-548, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29113519

RESUMO

RATIONALE: Patients with radiation-induced enteropathy (RE) after cancer treatment show similar symptoms as patients with irritable bowel syndrome (IBS). The low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet (LFD) is a widespread management strategy for IBS. We aimed to investigate if there may be a positive effect of LFD on symptoms and health-related quality of life (HRQOL) in patients with RE. METHODS: In an open non-controlled pilot study, 11 patients (all female) with RE-related IBS symptoms were recruited largely based on own initiative. All followed LFD for four weeks. IBS Severity Scoring System (IBS-SSS) and IBS Symptom Questionnaire (IBS-SQ) were used to assess symptoms. Short Form Nepean Dyspepsia Index (SF-NDI) and 12-item Short Form Health Survey (SF-12) evaluated HRQOL. A three day food record was used to estimate baseline intake of FODMAPs and to reveal dietary changes. RESULTS: FODMAP intake was successfully reduced, although LFD was found a burdensome intervention. IBS symptoms improved significantly based on mean total score of IBS-SSS and IBS-SQ, which changed from 310.2 ± 60.7 to 171.4 ± 107.2 (p = .001) and 27.4 ± 4.1 to 15.7 ± 10.1 (p = .002). HRQOL improved based on SF-NDI total score (30.5 ± 9.4 to 18.3 ± 8.2, p = .001) and based on mental (p = .047) and physical (p = .134) score of SF-12. Main additional dietary changes were reduced intake of energy, carbohydrates, and fiber. CONCLUSION: Our findings from this small-scaled pilot study indicate that the LFD may alleviate symptoms and improve HRQOL in patients with RE. Further controlled studies with larger sample size should be conducted to verify our results and hopefully enable implementation of LFD as a future part of the management strategy for RE.


Assuntos
Dieta , Enteropatias/dietoterapia , Neoplasias/radioterapia , Lesões por Radiação/dietoterapia , Adulto , Dissacarídeos , Feminino , Humanos , Síndrome do Intestino Irritável , Masculino , Pessoa de Meia-Idade , Monossacarídeos , Noruega , Oligossacarídeos , Projetos Piloto , Qualidade de Vida , Índice de Gravidade de Doença
2.
J Leukoc Biol ; 99(6): 971-8, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26609049

RESUMO

Chemokine receptors are key regulators of leukocyte trafficking but also have an important role in development, tumor growth, and metastasis. Among the chemokine receptors, CXCR4 is the only one that leads to perinatal death when genetically ablated in mice, indicating a more-widespread function in development. To identify pathways that are activated downstream of CXCR4, a solubilization protocol was elaborated, which allows for the isolation of the endogenous receptor from human cells in its near-native conformation. Solubilized CXCR4 is recognized by the conformation-sensitive monoclonal antibody 12G5 and retains the ability to bind CXCL12 in solution, which was abolished in the presence of receptor antagonists. Mass spectrometry of CXCR4 immunoprecipitates revealed a specific interaction with the pentameric eukaryotic translation initiation factor 2B. The observation that the addition of CXCL12 leads to the dissociation of eukaryotic translation initiation factor 2B from CXCR4 suggests that stimulation of the receptor may trigger the local protein synthesis required for efficient cell movement.


Assuntos
Fator de Iniciação 2B em Eucariotos/metabolismo , Receptores CXCR4/metabolismo , Sequência de Aminoácidos , Linhagem Celular , Cromatografia Líquida , Fator de Iniciação 2B em Eucariotos/química , Humanos , Imunoprecipitação , Peptídeos/química , Peptídeos/metabolismo , Ligação Proteica , Solubilidade , Espectrometria de Massas em Tandem
3.
PLoS One ; 10(2): e0116718, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25665127

RESUMO

BACKGROUND: In order to retrieve useful information from scientific literature and electronic medical records (EMR) we developed an ontology specific for Multiple Sclerosis (MS). METHODS: The MS Ontology was created using scientific literature and expert review under the Protégé OWL environment. We developed a dictionary with semantic synonyms and translations to different languages for mining EMR. The MS Ontology was integrated with other ontologies and dictionaries (diseases/comorbidities, gene/protein, pathways, drug) into the text-mining tool SCAIView. We analyzed the EMRs from 624 patients with MS using the MS ontology dictionary in order to identify drug usage and comorbidities in MS. Testing competency questions and functional evaluation using F statistics further validated the usefulness of MS ontology. RESULTS: Validation of the lexicalized ontology by means of named entity recognition-based methods showed an adequate performance (F score = 0.73). The MS Ontology retrieved 80% of the genes associated with MS from scientific abstracts and identified additional pathways targeted by approved disease-modifying drugs (e.g. apoptosis pathways associated with mitoxantrone, rituximab and fingolimod). The analysis of the EMR from patients with MS identified current usage of disease modifying drugs and symptomatic therapy as well as comorbidities, which are in agreement with recent reports. CONCLUSION: The MS Ontology provides a semantic framework that is able to automatically extract information from both scientific literature and EMR from patients with MS, revealing new pathogenesis insights as well as new clinical information.


Assuntos
Ontologias Biológicas , Registros Eletrônicos de Saúde , Armazenamento e Recuperação da Informação , Esclerose Múltipla/classificação , PubMed , Antineoplásicos/uso terapêutico , Antirreumáticos/uso terapêutico , Biologia Computacional/métodos , Cloridrato de Fingolimode/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Descoberta do Conhecimento , Mitoxantrona/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Rituximab/uso terapêutico
4.
Mol Microbiol ; 72(1): 41-52, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19210624

RESUMO

The pathogenicity of mycobacterial infections depends on virulence factors that mediate survival inside host macrophages. These virulence factors are generally believed to be specific for pathogenic species and absent or mutated in non-pathogenic strains. The serine/threonine protein kinase G (PknG) mediates survival of mycobacteria within macrophages by blocking lysosomal delivery. Here we describe a gene of the non-pathogenic species Mycobacterium smegmatis that is 78% identical with pknG of Mycobacterium tuberculosis and M. bovis bacillus Calmette-Guérin (BCG). When cloned into expression vectors, the M. smegmatis pknG orthologue produced an active kinase and performed the same function as its M. bovis BCG counterpart in intracellular survival. In addition, similar levels of pknG transcripts were found in M. bovis BCG and M. smegmatis. However, virtually no translation product of chromosomal pknG could be detected in M. smegmatis both after in vitro growth and after macrophage infection. This lack of efficient translation was shown to be caused by regulatory elements in the upstream region of the M. smegmatis gene. The data reveal dramatically increased translational efficiency of a virulence gene in a pathogenic mycobacterium compared with a non-pathogenic mycobacterium suggesting that changes in expression levels may underlie evolution of pknG and other pathogenicity genes in mycobacterium.


Assuntos
Proteínas de Bactérias/metabolismo , Proteínas Quinases Dependentes de GMP Cíclico/metabolismo , Mycobacterium smegmatis/genética , Fatores de Virulência/metabolismo , Sequência de Aminoácidos , Animais , Proteínas de Bactérias/genética , Clonagem Molecular , Proteínas Quinases Dependentes de GMP Cíclico/genética , Regulação Bacteriana da Expressão Gênica , Genes Bacterianos , Macrófagos/microbiologia , Camundongos , Camundongos Endogâmicos C57BL , Dados de Sequência Molecular , Mycobacterium smegmatis/enzimologia , Mycobacterium smegmatis/patogenicidade , Biossíntese de Proteínas , RNA Bacteriano/metabolismo , Alinhamento de Sequência , Análise de Sequência de DNA , Fatores de Virulência/genética
5.
Eur J Pharm Biopharm ; 69(1): 388-95, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18164928

RESUMO

Electrostatic interaction between opposite charge of drugs (insulin and benzoic acid) and chitosan was studied by 1H NMR, FTIR and isothermal titration calorimetry (ITC). No ionic interaction between the carboxyl group of benzoic acid and the amine group of chitosan could be detected. There was a minor change in the FTIR spectra of insulin-chitosan microparticles made of different concentrations of insulin. Exothermic heat of reaction between insulin and chitosan was obtained by ITC. However, the measured interaction enthalpy change (delta H) was possibly due to the conformational changes and the adsorption phenomena of insulin onto the surfaces of the particles but not to a binding interaction. The binding of tripolyphosphate, a widely used cross-linking agent, to pH 3.3 and pH 5 chitosan was also studied by ITC. The interaction enthalpy change of the binding between tripolyphosphate and chitosan indicated that tripolyphosphate provided a stronger interaction to pH 5 chitosan than to pH 3.3 chitosan. However, it can be stated that the electrostatical interaction forces between the tested molecules insulin, benzoic acid, and tripolyphosphate and chitosan are found to be very weak.


Assuntos
Química Farmacêutica/métodos , Quitosana/química , Tecnologia Farmacêutica/métodos , Ácido Benzoico/química , Calorimetria/métodos , Composição de Medicamentos , Interações Medicamentosas , Humanos , Concentração de Íons de Hidrogênio , Insulina/química , Íons , Espectroscopia de Ressonância Magnética/métodos , Polifosfatos/química , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA